Contact our expert data analytics team to gain competitive advantage using your intangible assets
The market approach establishes value by comparison to recent sales of comparable IP (this is complicated as IP is, by definition, unique and there is not a lot of publicly available sales data). The cost approach determines value on the basis of the estimated cost to create a replacement asset with similar utility (however, the relationship between cost and value is generally not linear). The income approach estimates the present value of forecast IP earnings, accounting for the asset’s development and operating risks (which are difficult to assess for early stage technology).
This article does not compare the pros and cons of the three approaches, but focuses on the application of the income approach to technology related IP (tech-IP).
The term ‘technology’ can cover a bundle of IP including patents, patent applications, designs, trade secrets, software and in-licensed IP. An obvious and essential first step is to clearly define the rights that are the subject of the valuation. As these rights can vary by jurisdiction, it is often appropriate to segment the valuation accordingly. Further segmentation can be beneficial if the competitive environment, or the potential of the tech-IP, differs by application.
For any asset category, it is essential to clarify the basis of value, which could be value in-current-use, market value (to a typical market participant) or special value (including synergies to a specific owner).
The illustration below shows the analytical ‘building blocks’ that are required to inform the assumptions needed to value tech-IP.
Analysis of the market size, growth and competitive forces is equally important for the valuation of technology as for business and brand valuations. Disruptive technology adds an extra layer of complexity, but that will be the subject of a future article. The best platform for market forecasting integrates insights from multiple landscapes: patent networks, consumer research, competitive forces, litigation and trends in IP deals.
Findings of the market analysis feed directly into assumptions of the target market’s size and growth. Along with the findings of the tech-IP’s commercial utility, the competitive forces analysis drives assumptions of the speed and extent of market penetration.
Incremental commercial utility
The earnings capability of tech-IP depends on its functional performance relative to alternatives - and the resulting economic benefits. Incremental utility can result from performance of the end-product, or from operating efficiencies stemming from the IP. Prior to commercialisation, relative
performance can be estimated through computer simulation and prototype studies. For consumer products, conjoint analysis can be used to gauge the demand impact of new features. The step from functional proof-of-concept to economic validation has caused many innovations to stumble, so it is essential to evaluate tech-IP’s costs and price implications.
Together with the analysis of competitive forces, the utility assessment drives assumptions of the rate and extent of the tech-IP’s market penetration. Other relevant factors are the extent of IP protection, relative price, the nature of the buying decision and access to complimentary assets.
Having highly differentiated technology with strong market potential is a good start. But unless the differentiating features have strong and enforceable IP protection, the differentiation will soon be eroded by competitors.
In addition to confirming the extent to which the subject IP covers the differentiating features of the technology, the appraisal should consider the validity and enforceability of patent claims, and design around risk. The likelihood of circumvention can be reduced by broad (and enforceable) patent claims or a patent thicket.
Blockbuster IP provides a significant uplift in utility, is difficult to design around, has a significant useful life and is not difficult to enforce.
Useful economic life
The remaining legal life of a patent provides the ceiling to its economic life. An assessment as to whether the economic life is shorter than the legal life should include the following factors:
Development hurdles and risk
For technology that is still in development, it is important to describe all development hurdles. For pharmaceutical IP the phases of clinical research and regulatory approval represent clearly defined phases. Some other industries have guidelines or generally accepted development milestones, such as: (i) unproven concept, (ii) model validation, (iii) proven small-scale prototype, (iv) proven commercial-scale prototype, and (v) commercial launch.
The development path provides a framework for estimating the probability of successfully reaching the market, the expected time to market and remaining R&D costs. Where there is significant development uncertainty, the valuer should consider using risk-weighted scenarios or real options methods of valuation.
As a ‘most likely’ probability of success can mask the breadth of possible outcomes, it is recommended that valuation reports disclose the development path and probability assumptions.
Market and asset risk
It is highly unlikely that the standalone risk profile of tech-IP is equal to the systematic risk of the enterprise that owns it. So corporate cost of capital is unlikely to be a suitable discount rate for tech-IP. The build-up method can be used to incorporate asset specific risks which should include the risk of technical obsolescence and risks that are intrinsic to patents and trade secrets.
IP valuations benefit from the use of more than one method and from commercial sense checks and sensitivity analysis. The valuer should ‘kick the tyres’ of each valuation assumption and the findings, and valuation reports should enable the user to do the same. For instance:
Contact Glasshouse Advisory expert valuations team to find out more about the income approach to value patents.
This article first appeared in IAM magazine. For further information please visit www.iam-magazine.com.